Current Studies

On a website of the US National Institutes of Health many ongoing clinical studies are listed. Please note that this list is not complete.

Here are some of the many current clinical studies.

THC / Dronabinol / Marinol
Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia at Hadassah Medical Organization, Jerusalem, Israel.
For more studies please click here.

Nabilone / Cesamet
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis at University of Manitoba, Winnipeg, Canada.
For more studies please click here.

Nabiximols / Sativex
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer in the United States, the UK and Germany.
For more studies please click here.

Cannabidiol (CBD)
Cannabidiol for Inflammatory Bowel Disease at Meir Medical Center, Kefar Saba, Israel.
For more studies please click here.

Smoked / Inhaled Cannabis
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS at New York State Psychiatric Institute, USA.
Effects of Vaporized Marijuana on Neuropathic Pain at CTSC Clinical Research Center, Sacramento, United States.
For more studies please click here.

Contacto

Você esta aqui:Home > Sobre nós > Introduction

Introduction

The International Association for Cannbinoid Medicines (IACM) was founded in March 2000. The aim of the association is to advance knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics especially with regard to their therapeutic potential. The mission is achieved in particular through the following actions:

Support for research into cannabis products and the endocannabinoid system;
Promotion of exchange of information between researchers, health care practitioners, patients and the public;
Preparation and dissemination of reliable information on the pharmacology, toxicology and therapeutic potential of cannabis and modulators of the endocannabinoid system;
Monitoring and documentation of national and international developments with respect to cannabinoid therapeutics;
Co-operation with other organisations and associations sharing the mission and goals of the IACM

The IACM declares that it is the right of doctors to be able to discuss the medicinal use of cannabis with their patients.

Membership

There are regular and associate members. Regular members elect the board of directors consisting of up to ten members and decide on the guidelines of the association. Associate members elect up to two patient representatives The patient representatives may participate with equal rights in the meetings of the Board of Directors. The complete statutory articles of the IACM can be downloaded here as a pdf file.

Publications

Members receive the newsletter of IACM (IACM-News). The IACM Bulletin is published in several languages on the internet. Free subscription with the online-form.

IACM Conference 2013

7th Conference on Cannabinoids in Medicine

The IACM Board of Directors would like to invite you to its 7th conference on Cannabinoids in September 2013 in Cologne.

European Workshop

6th European Workshop on Cannabinoids

18-20 April 2013
Trinity College Dublin, Ireland

Conference Website

Canadá

The University of British Columbia in partnership with the ICRS and the CCIC will organize “Cannabinoids in Clinical Practice” on 21 June 2013, a full day continuing medical education (CME) event.
More